Benefits from 18F-FDG PET-CT-Based Radiotherapy Planning in Stage III Non-Small-Cell Lung Cancer: A Prospective Single-Center Study
Cancers · 13.06.2025 · 17 (12) · 1969
DOI: 10.3390/cancers17121969 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 13.06.2025. Verfasst von Admir Mulita und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy/Oncology, School of Medicine, Democritus University of Thrace, 68100 Alexandroupolis, Greece. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Lung cancer is the leading cause of cancer-related mortality worldwide. Accurate radiotherapy (RT) planning alongside chemotherapy and immunotherapy is critical for improving treatment outcomes for inoperable non-metastatic cases. Conventional computed tomography (CT)-based planning may be inadequate for accurately identifying tumor margins and the location of nodal disease. We investigated whether 18F-labeled fluorodeoxyglucose positron emission tomography (18F-FDG PET-CT) imaging can assist in target volume delineation for primary, nodal, and metastatic disease in the RT planning and overall therapeutic planning of patients.
Methods
In this single-center, prospective study, we recruited 34 patients with histologically confirmed locally advanced non-small-cell lung carcinoma (NSCLC). All patients underwent 18F-FDG PET-CT-based RT simulation. Two sequential RT plans were created by the same radiation oncologist: one based on CT alone and the other PET-CT. Planning target volumes (PTVs) and PET-CT-guided adjustments were analyzed to assess their impact. Standardized protocols for immobilization, imaging, target delineation, and dose prescription were applied.
Results
A total of 34 patients (31 males and 3 females) were recruited in the study. 18F-FDG PET-CT detected distant metastases in 7/34 (20.6%) patients, altering the overall therapeutic plan in 4/34 (11.8%) and allowing radical RT in 3 of them who had oligometastatic disease (8.8%). It modified RT planning in 26/34 (76.5%) patients and clarified malignancy in atelectatic areas. Nodal involvement was identified in 3/34 patients (8.8%) and excluded in 3/34 cases, avoiding unnecessary nodal irradiation. Additional involved nodes were revealed in 12/34 (35.3%) patients, requiring dose escalation. Overall, changes to the tumor PTV were made in 23/30 (76.6%) and to the nodal PTV in 19/30 (63.3%) cases (p < 0.0001). Primary tumor and nodal PTVs increased in 20/34 (66.7%) and 13/34 (43.3%), respectively.
Conclusions
18F-FDG PET-CT significantly improves RT planning by more precisely defining tumor and nodal volumes, identifying undetected lesions, and guiding dose adaptation. Larger long-term studies are required to confirm potential locoregional control and survival improvements.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiotherapy/Oncology, School of Medicine, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
- Department of Nuclear Medicine, School of Medicine, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
- Medical Physics Laboratory, School of Medicine, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
- Department of Pneumonology, Medical School, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
- Department of Pathology, School of Medicine, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
ORCID-Profile: Eleni Bekou, Christos Nanos, Michael I Koukourakis
Zitieren
APA
Mulita, A., Valsamaki, P., Bekou, E., Anevlavis, S., Nanos, C., Zisimopoulos, A., Giatromanolaki, A., & Koukourakis, M. I. (2025). Benefits from 18F-FDG PET-CT-Based Radiotherapy Planning in Stage III Non-Small-Cell Lung Cancer: A Prospective Single-Center Study. Cancers, 17(12), 1969. https://doi.org/10.3390/cancers17121969
Vancouver
Mulita A, Valsamaki P, Bekou E, Anevlavis S, Nanos C, Zisimopoulos A, et al. Benefits from 18F-FDG PET-CT-Based Radiotherapy Planning in Stage III Non-Small-Cell Lung Cancer: A Prospective Single-Center Study. Cancers. 2025;17(12):1969. doi:10.3390/cancers17121969
BibTeX
@article{Mulita2025,
author = {Mulita, Admir and Valsamaki, Pipitsa and Bekou, Eleni and Anevlavis, Stavros and Nanos, Christos and Zisimopoulos, Athanasios and Giatromanolaki, Alexandra and Koukourakis, Michael I},
title = {Benefits from 18F-FDG PET-CT-Based Radiotherapy Planning in Stage III Non-Small-Cell Lung Cancer: A Prospective Single-Center Study},
journal = {Cancers},
year = {2025},
volume = {17},
number = {12},
pages = {1969},
doi = {10.3390/cancers17121969}
}
EUVIMED